For U.S. Healthcare Professionals Only Sanofi Genzyme

The only microtubule inhibitor approved in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen.

CareASSIST Patient Support Program

CareASSIST™ logo

Resources and support for your eligible patients

CareASSIST offers access support for eligible patients prescribed JEVTANA.

Access and Reimbursement

Access and Reimbursement

Assistance navigating the insurance
process, including benefits investigations,
claims assistance, and information about
prior authorizations and appeals.

See what's offered 

Financial Assistance

Financial Assistance

Eligible patients may qualify to
receive JEVTANA at no cost.

Learn about eligibility 

Resource Support

Resource Support

Information on independent support
services for patients and caregivers, as
well as product ordering and
replacement information.

Find support 

CareASSIST™ logo

To learn more about CareASSIST


IMPORTANT SAFETY INFORMATION

WARNING: NEUTROPENIA AND HYPERSENSITIVITY

  • Neutropenic deaths have been reported. Obtain frequent blood counts to monitor for neutropenia. JEVTANA is contraindicated in patients with neutrophil counts of ≤1,500 cells/mm3. Primary prophylaxis with G-CSF is recommended in patients with high-risk clinical features.
  • Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm. Severe hypersensitivity reactions require immediate discontinuation of the JEVTANA infusion and administration of appropriate therapy. Patients should receive premedication. JEVTANA is contraindicated in patients who have a history of severe hypersensitivity reactions to cabazitaxel or to other drugs formulated with polysorbate 80.

You are about to leave jevtanapro.com


You are leaving jevtanapro.com to view another Sanofi Genzyme Corporation website.



Continue 
Cancel